Advertisement
Australia markets close in 14 minutes

  • ALL ORDS

    7,866.40
    -143.00 (-1.79%)
     

  • ASX 200

    7,616.20
    -136.30 (-1.76%)
     

  • AUD/USD

    0.6429
    -0.0016 (-0.25%)
     

  • OIL

    86.03
    +0.62 (+0.73%)
     

  • GOLD

    2,403.30
    +20.30 (+0.85%)
     

  • Bitcoin AUD

    97,527.88
    -4,391.52 (-4.31%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • AUD/EUR

    0.6050
    -0.0009 (-0.16%)
     

  • AUD/NZD

    1.0905
    -0.0003 (-0.03%)
     

  • NZX 50

    11,804.84
    -111.94 (-0.94%)
     

  • NASDAQ

    17,706.83
    -296.65 (-1.65%)
     

  • FTSE

    7,965.53
    -30.05 (-0.38%)
     

  • Dow Jones

    37,735.11
    -248.13 (-0.65%)
     

  • DAX

    18,026.58
    +96.26 (+0.54%)
     

  • Hang Seng

    16,339.75
    -260.71 (-1.57%)
     

  • NIKKEI 225

    38,502.08
    -730.72 (-1.86%)
     

Was This Acquisition a Savvy Play by This Big Pharma Stock?

Kody Kester, The Motley Fool
·3-min read
Was This Acquisition a Savvy Play by This Big Pharma Stock?

Earlier this month, U.K.-based drugmaker GSK (NYSE: GSK) reached a deal to buy Canadian biotech company Bellus Health (NASDAQ: BLU) for $2 billion in cash. Should GSK's deal for Bellus Health be approved by regulatory authorities and a two-thirds majority of the latter's shareholders, the former will pick up a promising drug candidate, camlipixant, that aims to treat refractory chronic cough (RCC). Surprisingly, there are no approved therapies for RCC in the United States or the European Union.

Continue reading